Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions

Launched by PETER MACCALLUM CANCER CENTRE, AUSTRALIA · Oct 23, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to better identify and understand invasive fungal infections, specifically those caused by a fungus called Aspergillus. Researchers will use a special technique called Positron Emission Tomography (PET) with a radioactive marker that attaches to a component of the fungus, helping to see where the infection is located in the body. This study is currently looking for participants who are diagnosed with a fungal infection and are at least 18 years old.

To be part of this study, you need to give your written consent and be diagnosed with an invasive fungal infection within the last two weeks. You should also have specific imaging results showing signs of this infection. If you participate, you will undergo imaging scans to help researchers learn more about how this method can improve the detection of fungal infections. It's important to note that pregnant or breastfeeding women, as well as those who have received iron infusions recently, cannot participate. This trial aims to enhance our understanding of fungal infections and potentially lead to better ways to treat them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient has provided written informed consent
• • 2. Aged 18 years or older at written informed consent
• • 3. Within 2 weeks of proven or probable invasive fungal infection (IFI) diagnosis as per EORTC criteria
• • 4. Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter
• • 5. Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up
• Exclusion Criteria:
• • 1. Women who are pregnant or lactating.
• • 2. Iron infusion within one week prior to scan